Rodelo-Haad Cristian, Pendón-Ruiz de Mier M Victoria, Díaz-Tocados Juan Miguel, Martin-Malo Alejandro, Santamaria Rafael, Muñoz-Castañeda Juan Rafael, Rodríguez Mariano
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain.
University of Córdoba, Córdoba, Spain.
Front Cell Dev Biol. 2020 Nov 12;8:543099. doi: 10.3389/fcell.2020.543099. eCollection 2020.
Some of the critical mechanisms that mediate chronic kidney disease (CKD) progression are associated with vascular calcifications, disbalance of mineral metabolism, increased oxidative and metabolic stress, inflammation, coagulation abnormalities, endothelial dysfunction, or accumulation of uremic toxins. Also, it is widely accepted that pathologies with a strong influence in CKD progression are diabetes, hypertension, and cardiovascular disease (CVD). A disbalance in magnesium (Mg) homeostasis, more specifically hypomagnesemia, is associated with the development and progression of the comorbidities mentioned above, and some mechanisms might explain why low serum Mg is associated with negative clinical outcomes such as major adverse cardiovascular and renal events. Furthermore, it is likely that hypomagnesemia causes the release of inflammatory cytokines and C-reactive protein and promotes insulin resistance. Animal models have shown that Mg supplementation reverses vascular calcifications; thus, clinicians have focused on the potential benefits that Mg supplementation may have in humans. Recent evidence suggests that Mg reduces coronary artery calcifications and facilitates peripheral vasodilation. Mg may reduce vascular calcification by direct inhibition of the Wnt/β-catenin signaling pathway. Furthermore, Mg deficiency worsens kidney injury induced by an increased tubular load of phosphate. One important consequence of excessive tubular load of phosphate is the reduction of renal tubule expression of α-Klotho in moderate CKD. Low Mg levels worsen the reduction of Klotho induced by the tubular load of phosphate. Evidence to support clinical translation is yet insufficient, and more clinical studies are required to claim enough evidence for decision-making in daily practice. Meanwhile, it seems reasonable to prevent and treat Mg deficiency. This review aims to summarize the current understanding of Mg homeostasis, the potential mechanisms that may mediate the effect of Mg deficiency on CKD progression, CVD, and mortality.
介导慢性肾脏病(CKD)进展的一些关键机制与血管钙化、矿物质代谢失衡、氧化和代谢应激增加、炎症、凝血异常、内皮功能障碍或尿毒症毒素蓄积有关。此外,对CKD进展有重大影响的疾病是糖尿病、高血压和心血管疾病(CVD),这一点已得到广泛认可。镁(Mg)稳态失衡,更具体地说是低镁血症,与上述合并症的发生和进展相关,一些机制或许可以解释为什么低血清镁与不良临床结局相关,如主要不良心血管和肾脏事件。此外,低镁血症可能导致炎性细胞因子和C反应蛋白的释放,并促进胰岛素抵抗。动物模型表明,补充镁可逆转血管钙化;因此,临床医生关注补充镁对人类可能带来的潜在益处。最近的证据表明,镁可减少冠状动脉钙化并促进外周血管舒张。镁可能通过直接抑制Wnt/β-连环蛋白信号通路来减少血管钙化。此外,镁缺乏会使因肾小管磷酸盐负荷增加所致的肾损伤恶化。肾小管磷酸盐负荷过高的一个重要后果是中度CKD患者肾小管α-klotho表达降低。低镁水平会加重磷酸盐肾小管负荷所致的klotho降低。支持临床转化的证据尚不充分,需要更多临床研究来获取足够证据以用于日常临床决策。与此同时,预防和治疗镁缺乏似乎是合理的。本综述旨在总结目前对镁稳态的认识,以及可能介导镁缺乏对CKD进展、CVD和死亡率影响的潜在机制。